Saudi Chemical CoSAU:2230 +0.86%81 EBITDA Margin % is 7.66% as of Mar. 2026, which is 26% above its 10-year median of 6.10. GuruFocus rates SAU:2230 with a GF Score™ of 81/100 and a GF Value™ of ﷼8.54 (Fairly Valued). The stock has 3 warning signs investors should review. Among 953 Drug Manufacturers companies, Saudi Chemical Co ranks worse than 61.39% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Saudi Chemical Co's EBITDA for the
three
months ended in Mar. 2026 was ﷼132 Mil. Saudi Chemical Co's Revenue for the
three
months ended in Mar. 2026 was ﷼1,727 Mil. Therefore, Saudi Chemical Co's EBITDA margin for the quarter that ended in Mar. 2026 was 7.66%.
Saudi Chemical Co (SAU:2230) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Saudi Chemical Co EBITDA Margin % Related Terms
Saudi Chemical Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Saudi Chemical Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAU:2230 vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Saudi Chemical Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saudi Chemical Co EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Saudi Chemical Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Saudi Chemical Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saudi Chemical Co (SAU:2230) has a EBITDA Margin % of 7.66% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Saudi Chemical Co and its competitors. This is 26% above median its historical median of 6.10. Over the past decade, Saudi Chemical Co's EBITDA Margin % has ranged from 0.69 to 8.02. According to the industry distribution chart, Saudi Chemical Co ranks #585 out of 953 companies in the Drug Manufacturers industry, placing it in the top 61.4%.
Is Saudi Chemical Co's EBITDA Margin % too high?
Saudi Chemical Co's current EBITDA Margin % of 7.66% is 26% above median its 10-year median of 6.10. Over the past 10 years, this metric has ranged from a low of 0.69 to a high of 8.02. The Drug Manufacturers industry median EBITDA Margin % is 12.54. Saudi Chemical Co's value of 7.66% is 38.9% below this industry median. Based on the distribution chart, Saudi Chemical Co ranks #585 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Saudi Chemical Co has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Saudi Chemical Co's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Saudi Chemical Co ranks #585 out of 953 companies for EBITDA Margin %. This places Saudi Chemical Co in the lower half of its industry. The industry median EBITDA Margin % is 12.54. Saudi Chemical Co's value of 7.66% is 38.9% below this benchmark. Historically, Saudi Chemical Co's own EBITDA Margin % has ranged from 0.69 to 8.02 over the past decade. While the company's 10-year median is 6.10 vs. the industry median of 12.54, Saudi Chemical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.54, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Saudi Chemical Co's current EBITDA Margin % of 7.66% is 38.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Saudi Chemical Co and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Saudi Chemical Co's current EBITDA Margin % is 7.66%, which is 26% above median its own 10-year median of 6.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saudi Chemical Co stock overvalued right now?
Based on GuruFocus' analysis, Saudi Chemical Co (SAU:2230) is currently considered Fairly Valued. The stock's GF Value™ is ﷼8.54, compared to a current price of ﷼8.18 — trading 4.2% below its estimated fair value. The current EBITDA Margin % is 7.66%, which is 26% above median its 10-year median of 6.10 and 38.9% below the Drug Manufacturers industry median of 12.54. Saudi Chemical Co's overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Saudi Chemical Co (SAU:2230), the current EBITDA Margin % is 7.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Saudi Chemical Co (SAU:2230) Overvalued in 2026?
Based on GuruFocus' analysis, Saudi Chemical Co stock appears to be undervalued.
The current stock price of ﷼8.18 is trading 4.2% below its estimated GF Value™ of ﷼8.54.
GuruFocus considers Saudi Chemical Co to be Fairly Valued.
Key valuation signals for SAU:2230:
EBITDA Margin %: 7.66% (26% above median its 10-year median of 6.10)
GF Value™: ﷼8.54 vs. price of ﷼8.18 (4.2% below fair value)
Industry Position: 38.9% below the Drug Manufacturers median (#585 of 953)
No single metric tells the full story. See the SAU:2230 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Saudi Chemical Co, along with its subsidiaries, is engaged in the manufacturing and distribution of explosives and their derivatives. Its other business operations include providing technical support services in explosions, wholesale and retail trading in medicines, medical materials and syrups, pharmaceutical preparations, medical and surgical tools, and equipment, supplies of hospitals and medical centers, and the manufacture of ammonium nitrate. The company operates in three segments: Explosives, Medicines & medical supplies, and Production of Ammonium Nitrate. It generates the majority of its revenue from Medicines & medical supplies.
81GF Score
Get the complete analysis for SAU:2230
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SAU:2230 has been successfully added to your 
